Osteosarcoma of rib treated with regorafenib: a case report
Abstract
Keywords
Supporting Institution
Thanks
References
- Mirabello L, Troisi R J, Savage S A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43. doi: 10.1002/cncr.24121.
- Davis L E, Bolejack V, Ryan C W, Ganjoo K N, Loggers E T, Chawla S, Agulnik M, Livingston M B, Reed D, Keedy V, Rushing D, Okuno S, Reinke D K, Riedel R F, Attia S, Mascarenhas L, Maki R G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol . 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374.
- Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3.
Details
Primary Language
English
Subjects
Internal Diseases
Journal Section
Case Report
Authors
Orkun Sakar
*
0000-0002-1624-4339
Türkiye
Cemre Uçaryılmaz
0000-0002-5758-1120
Türkiye
Türkkan Evrensel
0000-0002-9732-5340
Türkiye
Cengiz Gebitekin
0000-0001-8718-9499
Türkiye
Publication Date
March 7, 2021
Submission Date
February 7, 2021
Acceptance Date
March 6, 2021
Published in Issue
Year 2021 Volume: 3 Number: Supplement 1